Currently out of the existing stock ratings of Kostas Biliouris, 40 are a BUY (68.97%), 18 are a HOLD (31.03%).

Kostas Biliouris

Work Performance Price Targets & Ratings Chart

Analyst Kostas Biliouris, currently employed at BMO, carries an average stock price target met ratio of 33.49% that have a potential upside of 38.43% achieved within 122 days.

Kostas Biliouris’s has documented 125 price targets and ratings displayed on 17 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on SRPT, Sarepta Therapeutics at 21-Sep-2025.

Wall Street Analyst Kostas Biliouris

Analyst best performing recommendations are on BEAM (BEAM THERAPEUTICS ).
The best stock recommendation documented was for BEAM (BEAM THERAPEUTICS ) at 7/18/2022. The price target of $61 was fulfilled within 1 day with a profit of $2.99 (5.15%) receiving and performance score of 51.54.

Average potential price target upside

BEAM Beam Therapeutics  CNTA Centessa Pharmaceuticals PLC ADR CRSP Crispr Therapeutics AG DTIL Precision BioSciences GRPH Graphite Bio LEGN Legend Biotech Corp NTLA Intellia Therapeutics VERV Verve Therapeutics BMRN Biomarin Pharmaceutical ALNY Alnylam Pharmaceuticals FDMT 4D Molecular Therapeutics  SRPT Sarepta Therapeutics KRRO Frequency Therapeutics IONS Ionis Pharmaceuticals JSPR Jasper Therapeutics RCKT Rocket Pharmaceuticals SLN Silence Therapeutics PLC

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy

$41

$15.02 (57.81%)

$30

10 days ago
(08-Oct-2025)

2/4 (50%)

$13.13 (47.11%)

147

Hold

$21

$-4.98 (-19.17%)

$25

2 months 13 days ago
(05-Aug-2025)

11/11 (100%)

$2.7 (14.75%)

145

Buy

$55

$29.02 (111.70%)

$78

5 months 12 days ago
(06-May-2025)

0/4 (0%)

$38.77 (238.88%)

Buy

$70

$44.02 (169.44%)

$105

5 months 12 days ago
(06-May-2025)

0/3 (0%)

$53.77 (331.30%)

$40

$14.02 (53.96%)

$57

5 months 26 days ago
(22-Apr-2025)

2/5 (40%)

$20.13 (101.31%)

4

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

Which stock is Kostas Biliouris is most bullish on?

Potential upside of $27.49 has been obtained for SRPT (SAREPTA THERAPEUTICS)

Which stock is Kostas Biliouris is most reserved on?

Potential downside of -$11.67 has been obtained for ALNY (ALNYLAM PHARMACEUTICALS)

What Year was the first public recommendation made by Kostas Biliouris?

On 2022

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?